iBio (IBIO) Payables (2011 - 2026)
iBio (IBIO) posted quarterly Payables of $3.0 million for Q1 2026, up 57.09% year-over-year from $1.9 million in Q1 2025, and up 14.36% quarter-over-quarter from $2.7 million in Q4 2025.
iBio (IBIO) Payables (2011 - 2026) Analysis & Trends
iBio (IBIO) has reported Payables for 16 consecutive years, with $3.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables rose 57.09% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $3.0 million (up 57.09% YoY), while the FY2025 annual figure was $3.0 million, up 514.14% from the prior year.
- Payables advanced to $3.0 million in Q1 2026 per IBIO's latest filing, from $2.7 million in the prior quarter.
- Across five years, Payables topped out at $27.0 million in Q3 2022 and bottomed at $481000.0 in Q2 2024.
- Historically, Payables has averaged $9.9 million across 5 years, with a median of $5.3 million in 2022.
- Annual changes were most pronounced in 2022 — Payables surged 1078.36% — and 2024, when it tumbled 96.75%.
- iBio's Payables stood at $20.0 million in 2022, then decreased by 27.48% to $14.5 million in 2023, then slumped by 94.14% to $851000.0 in 2024, then surged by 211.87% to $2.7 million in 2025, then gained by 14.36% to $3.0 million in 2026.
- Business Quant data shows IBIO's Payables at $3.0 million in Q1 2026, $2.7 million in Q4 2025, and $3.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - | 35.57 Mn |
| 10 | iBio | 176.41 Mn | 176.41 Mn | - | 3.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.04 Mn |
| Dec 31, 2025 | 2.65 Mn |
| Sep 30, 2025 | 3.53 Mn |
| Jun 30, 2025 | 2.95 Mn |
| Mar 31, 2025 | 1.93 Mn |
| Dec 31, 2024 | 851,000.00 |
| Sep 30, 2024 | 1.08 Mn |
| Jun 30, 2024 | 481,000.00 |
| Mar 31, 2024 | 13.88 Mn |
| Dec 31, 2023 | 14.51 Mn |
| Sep 30, 2023 | 14.54 Mn |
| Jun 30, 2023 | 14.79 Mn |
| Mar 31, 2023 | 15.71 Mn |
| Dec 31, 2022 | 20.01 Mn |
| Sep 30, 2022 | 27.01 Mn |
| Jun 30, 2022 | 26.43 Mn |
| Mar 31, 2022 | 5.28 Mn |
| Dec 31, 2021 | 2.74 Mn |
| Sep 30, 2021 | 2.29 Mn |
| Jun 30, 2021 | 2.85 Mn |